AR096100A2 - Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hiv - Google Patents
Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hivInfo
- Publication number
- AR096100A2 AR096100A2 ARP140101722A ARP140101722A AR096100A2 AR 096100 A2 AR096100 A2 AR 096100A2 AR P140101722 A ARP140101722 A AR P140101722A AR P140101722 A ARP140101722 A AR P140101722A AR 096100 A2 AR096100 A2 AR 096100A2
- Authority
- AR
- Argentina
- Prior art keywords
- crystal
- hiv
- oxoquinoline
- derivative
- ray powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Abstract
Reivindicación 1: Un cristal (cristal de forma II) de ácido 6-(3-cloro-2-fluorobencil)-1-[(S)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico, caracterizado porque posee un modelo de difracción de polvo con rayos X que posee crestas de difracción característica en ángulos de difracción 2q(º) de 6,56; 13,20; 19,86; 20,84; 21,22; 25,22º medido por difractómetro de polvo con rayos X. Reivindicación 2: Un cristal (cristal de forma III) de ácido 6-(3-cloro-2-fluorobencil)-1-[(S)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico, caracterizado porque posee un modelo de difracción de polvo con rayos X que posee crestas de difracción característica en ángulos de difracción 2q(º) de 8,54; 14,02; 15,68; 17,06; 17,24; 24,16; 25,74º medido por difractómetro de polvo con rayos X. Reivindicación 5: Un cristal mezcla caracterizado por que comprende el cristal de acuerdo con la reivindicación 1 y el cristal de acuerdo con la reivindicación 2 ó 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004150979 | 2004-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096100A2 true AR096100A2 (es) | 2015-12-09 |
Family
ID=35079161
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102058A AR049280A1 (es) | 2004-05-20 | 2005-05-19 | Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv. |
ARP140101722A AR096100A2 (es) | 2004-05-20 | 2014-04-25 | Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hiv |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102058A AR049280A1 (es) | 2004-05-20 | 2005-05-19 | Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv. |
Country Status (30)
Country | Link |
---|---|
US (6) | US7635704B2 (es) |
EP (4) | EP2514746A1 (es) |
JP (1) | JP3754064B2 (es) |
KR (1) | KR20080064909A (es) |
CN (1) | CN1956961B (es) |
AR (2) | AR049280A1 (es) |
AU (1) | AU2005245296B2 (es) |
BR (1) | BRPI0510114B8 (es) |
CA (1) | CA2566922C (es) |
CY (1) | CY1113010T1 (es) |
DK (2) | DK1636190T3 (es) |
ES (2) | ES2388441T3 (es) |
FI (2) | FI3281939T3 (es) |
HK (1) | HK1083341A1 (es) |
HR (2) | HRP20231588T3 (es) |
IL (1) | IL179250A0 (es) |
LT (1) | LT3281939T (es) |
MX (1) | MXPA06013405A (es) |
MY (1) | MY134672A (es) |
NO (6) | NO20230913A1 (es) |
NZ (1) | NZ551839A (es) |
PE (2) | PE20120361A1 (es) |
PL (2) | PL3281939T3 (es) |
PT (2) | PT3281939T (es) |
RS (2) | RS52375B (es) |
RU (1) | RU2330845C1 (es) |
SI (2) | SI3281939T1 (es) |
TW (1) | TWI329015B (es) |
WO (1) | WO2005113508A1 (es) |
ZA (1) | ZA200610647B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6891227B2 (en) | 2002-03-20 | 2005-05-10 | International Business Machines Corporation | Self-aligned nanotube field effect transistor and method of fabricating same |
EP3406596A1 (en) * | 2002-11-20 | 2018-11-28 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
AU2006332664B2 (en) * | 2005-12-30 | 2013-03-14 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of HIV integrase inhibitors |
EP1978960A4 (en) * | 2006-02-01 | 2009-12-02 | Japan Tobacco Inc | USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION |
WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
US8383819B2 (en) | 2006-03-06 | 2013-02-26 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
AP2985A (en) | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
CA2661943C (en) | 2006-09-12 | 2015-11-03 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
NZ579802A (en) * | 2007-02-23 | 2012-04-27 | Gilead Sciences Inc | Compounds for improving the efficacy of other drugs |
US20110009411A1 (en) * | 2007-06-29 | 2011-01-13 | Gilead Sciences ,Inc. | Therapeutic compositions and the use thereof |
AP2965A (en) * | 2007-06-29 | 2014-09-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
SG190618A1 (en) | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
SI2393485T1 (sl) | 2009-02-06 | 2015-10-30 | Gilead Sciences, Inc. | Dvoslojne tablete, ki vsebujejo elvitegravir, cobicistat, emtricitabin in tenofovir |
WO2010137032A2 (en) * | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
WO2011004389A2 (en) * | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
CN102212032B (zh) * | 2011-04-20 | 2013-07-31 | 复旦大学 | 一种5-羟基喹诺酮类衍生物及其制备方法和用途 |
MX2015000164A (es) | 2012-07-06 | 2015-08-12 | Genentech Inc | Benzamidas n-sustituidas y metodos para usarlas. |
ES2608860T3 (es) | 2012-08-03 | 2017-04-17 | Gilead Sciences, Inc. | Proceso e intermedios para preparar inhibidores de la integrasa |
CN103819402B (zh) * | 2012-11-17 | 2016-03-30 | 上海迪赛诺化学制药有限公司 | 埃替拉韦中间体及其制备方法和应用 |
CN103864682B (zh) * | 2012-12-18 | 2016-12-28 | 上海迪赛诺化学制药有限公司 | 一种制备iii型埃替拉韦晶体的方法 |
KR102040007B1 (ko) | 2012-12-21 | 2019-11-05 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
ES2645192T3 (es) | 2013-07-12 | 2017-12-04 | Gilead Sciences, Inc. | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
CN105315203A (zh) * | 2014-06-06 | 2016-02-10 | 上海迪赛诺化学制药有限公司 | 一种v型埃替拉韦晶体及其制备方法 |
TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
EP3736274A1 (en) | 2015-04-02 | 2020-11-11 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CN106008195B (zh) * | 2016-05-19 | 2018-08-03 | 绍兴文理学院 | 一种2,4-二氟-5-碘苯甲酸的制备方法 |
EP3984536A1 (en) * | 2020-10-19 | 2022-04-20 | Centre national de la recherche scientifique | Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
JPS567162B1 (es) | 1970-09-14 | 1981-02-16 | ||
JPS4826772A (es) | 1971-08-11 | 1973-04-09 | ||
JPS6450979A (en) | 1987-08-21 | 1989-02-27 | Hitachi Shipbuilding Eng Co | Method for discriminating whistle sound |
JPH0651229B2 (ja) | 1989-07-31 | 1994-07-06 | 新日本製鐵株式会社 | プラズマアーク溶接方法および装置 |
IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | 8−ジフルオロメトキシキノリン−3−カルボン酸誘導体 |
JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | 7−フェニルピペラジニルキノリン−3−カルボン酸誘導体 |
AU683569B2 (en) | 1994-07-18 | 1997-11-13 | Sankyo Company Limited | Trifluoromethylquinolinecarboxylic acid derivative |
JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
JPH0826772A (ja) | 1994-07-22 | 1996-01-30 | Sony Corp | 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法 |
ES2171260T3 (es) | 1996-04-12 | 2002-09-01 | Us Gov Health & Human Serv | Compuestos derivados de acridona utiles como agentes antineoplasicos y antirretroviricos. |
FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Icam−1産生阻害剤 |
GB9721964D0 (en) | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
US6399629B1 (en) | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
JP2004513134A (ja) | 2000-10-12 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類 |
CA2425625A1 (en) | 2000-10-12 | 2002-07-18 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
ATE411292T1 (de) | 2001-03-01 | 2008-10-15 | Shionogi & Co | Stickstoffhaltige heteroarylverbindungen mit hiv- integrase inhibierender wirkung |
JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
US20030138483A1 (en) * | 2001-05-25 | 2003-07-24 | Sergio Petriconi | Soft elastic capsules and compositions thereof |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
FR2827600A1 (fr) | 2001-07-20 | 2003-01-24 | Lipha | Derives acides de quinolone et leurs applications en therapeutique |
JP4035765B2 (ja) | 2002-10-31 | 2008-01-23 | 横河電機株式会社 | フーリエ変換型赤外線分光計 |
JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 |
EP3406596A1 (en) * | 2002-11-20 | 2018-11-28 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
EP3287130A1 (en) | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
-
2005
- 2005-05-18 MY MYPI20052258A patent/MY134672A/en unknown
- 2005-05-19 CN CN2005800161426A patent/CN1956961B/zh active Active
- 2005-05-19 NO NO20230913A patent/NO20230913A1/no unknown
- 2005-05-19 RS RS20120306A patent/RS52375B/en unknown
- 2005-05-19 EP EP12173572A patent/EP2514746A1/en not_active Withdrawn
- 2005-05-19 LT LTEP17186674.2T patent/LT3281939T/lt unknown
- 2005-05-19 DK DK05726243.8T patent/DK1636190T3/da active
- 2005-05-19 EP EP05726243A patent/EP1636190B1/en active Active
- 2005-05-19 PL PL17186674.2T patent/PL3281939T3/pl unknown
- 2005-05-19 WO PCT/JP2005/009604 patent/WO2005113508A1/en active Application Filing
- 2005-05-19 ES ES05726243T patent/ES2388441T3/es active Active
- 2005-05-19 RS RS20231092A patent/RS64845B1/sr unknown
- 2005-05-19 DK DK17186674.2T patent/DK3281939T3/da active
- 2005-05-19 MX MXPA06013405A patent/MXPA06013405A/es active IP Right Grant
- 2005-05-19 NZ NZ551839A patent/NZ551839A/en unknown
- 2005-05-19 ZA ZA200610647A patent/ZA200610647B/en unknown
- 2005-05-19 ES ES17186674T patent/ES2960824T3/es active Active
- 2005-05-19 SI SI200532315T patent/SI3281939T1/sl unknown
- 2005-05-19 PT PT171866742T patent/PT3281939T/pt unknown
- 2005-05-19 EP EP23203885.1A patent/EP4299563A3/en active Pending
- 2005-05-19 AU AU2005245296A patent/AU2005245296B2/en active Active
- 2005-05-19 EP EP17186674.2A patent/EP3281939B1/en active Active
- 2005-05-19 SI SI200531572T patent/SI1636190T1/sl unknown
- 2005-05-19 BR BRPI0510114A patent/BRPI0510114B8/pt active IP Right Grant
- 2005-05-19 RU RU2006145302/04A patent/RU2330845C1/ru active
- 2005-05-19 AR ARP050102058A patent/AR049280A1/es not_active Application Discontinuation
- 2005-05-19 JP JP2005147219A patent/JP3754064B2/ja active Active
- 2005-05-19 FI FIEP17186674.2T patent/FI3281939T3/fi active
- 2005-05-19 TW TW094116234A patent/TWI329015B/zh active
- 2005-05-19 PL PL05726243T patent/PL1636190T3/pl unknown
- 2005-05-19 HR HRP20231588TT patent/HRP20231588T3/hr unknown
- 2005-05-19 CA CA2566922A patent/CA2566922C/en active Active
- 2005-05-19 PT PT05726243T patent/PT1636190E/pt unknown
- 2005-05-19 KR KR1020087014768A patent/KR20080064909A/ko not_active Application Discontinuation
- 2005-05-20 PE PE2011002129A patent/PE20120361A1/es active IP Right Grant
- 2005-05-20 PE PE2005000561A patent/PE20060358A1/es active IP Right Grant
- 2005-05-20 US US11/133,471 patent/US7635704B2/en active Active
-
2006
- 2006-05-11 HK HK06105469.5A patent/HK1083341A1/xx unknown
- 2006-11-14 IL IL179250A patent/IL179250A0/en active IP Right Grant
- 2006-12-14 NO NO20065790A patent/NO339223B1/no unknown
-
2009
- 2009-08-10 US US12/538,694 patent/US8981103B2/en active Active
-
2012
- 2012-07-11 CY CY20121100621T patent/CY1113010T1/el unknown
- 2012-08-24 HR HRP20120681TT patent/HRP20120681T1/hr unknown
-
2014
- 2014-04-25 AR ARP140101722A patent/AR096100A2/es active IP Right Grant
-
2015
- 2015-01-09 US US14/593,946 patent/US20150361044A1/en not_active Abandoned
-
2016
- 2016-08-12 NO NO20161297A patent/NO20161297A1/no not_active Application Discontinuation
-
2017
- 2017-03-01 US US15/447,007 patent/US20180029989A1/en not_active Abandoned
-
2018
- 2018-07-20 US US16/041,458 patent/US20190185433A1/en not_active Abandoned
-
2019
- 2019-01-15 NO NO20190051A patent/NO20190051A1/no not_active Application Discontinuation
-
2020
- 2020-08-04 NO NO20200873A patent/NO20200873A1/no not_active Application Discontinuation
-
2021
- 2021-08-24 US US17/445,817 patent/US20220235009A1/en active Pending
-
2022
- 2022-06-17 NO NO20220690A patent/NO20220690A1/no not_active Application Discontinuation
-
2024
- 2024-03-20 FI FIC20240008C patent/FIC20240008I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096100A2 (es) | Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hiv | |
MY151071A (en) | Low-foaming preparations for crop protection | |
DE502006006185D1 (de) | Verfahren zur herstellung einer wässrigen suspension und einer pulverförmigen zubereitung eines oder mehrerer carotinoide | |
IL182086A0 (en) | Compositions for use against one or more pathogens | |
MX2010006370A (es) | Composiciones de activo antitranspirante que tienen un cromatograma sec que exhibe una intensidad de pico 4 sec elevada. | |
ZA200702700B (en) | Diagnostic compounds | |
DE60216066D1 (de) | Konzentrierte wasserlösliche granulatförmige pflanzenwachstumsregulatorformulierung und verfahren zu ihrer verwendung | |
CO6751287A2 (es) | Composición antigénetica de micobacteria | |
WO2007039825A3 (en) | Saccharide foamable compositions | |
SG161311A1 (en) | Novel use of spiegelmers | |
NZ596254A (en) | Cleanser compositions and methods for using the same comprising linalool, hinokitiol, diol and surfactant | |
UY29857A1 (es) | Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. | |
BRPI0814957B8 (pt) | composto, agente farmacêutico, e, uso do composto | |
AR067361A1 (es) | 4- cloro-4- alcoxi-1,1,1- trifluoro -2- butanonas, su preparacion y su uso para preparar 4- alcoxi-1,1,1- trifluoro-3 -buten-2- onas | |
WO2011056511A3 (en) | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase | |
AR068952A1 (es) | Procedimiento para la preparacion de medetomidina | |
TW200736227A (en) | New compounds III | |
MY155661A (en) | Novel 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof | |
CR10052A (es) | Proceso para la preparación de aminas | |
MX2016007436A (es) | Composiciones para el cuidado oral que comprenden carbonato de calcio y talco. | |
PH12019500690A1 (en) | Oral care composition | |
MX2017012947A (es) | Composicion auxiliar para el afeitado. | |
DE602005008607D1 (de) | Im mund zerfallende pharmazeutische zusammensetzung mit risperidon | |
WO2009024838A3 (en) | Impression and model components | |
UY29328A1 (es) | Aleaciones preparadas en base a ti, ru y a1 y su uso en la sentesis de clorato de sodio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |